Clinical trials: Rejection of Renal Transplant
Kidney Failure
Immune Monitoring in Sensitized Patients at Risk of Rejection
The purpose of this study is to test the effect of anti-rejection medications on your immune system
- Trial name
- PRISM (NCT03794817)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- University of California, San Francisco
Kidney Transplant, Kidney Disease, Chronic
KTRSensor Scotland Study: An Observational Study Into Predictors and Diagnosis of Kidney Transplant Rejection
An observational study capturing real world transplant patients in the post-operative setting aiming to further determine the utility of biomarkers to improve outcomes.
- Trial name
- KTRSensors (NCT06830473)
- Where
- 2 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- University of Edinburgh
Kidney Transplantation, Renal Transplant Recipients
Selective CD28 Blockade in Renal Transplant Recipients
The aim of this study is to evaluate the safety and efficacy of lulizumab, a CD28-specific domain antibody (CD28 dAb), compared to tacrolimus, as the primary immunosuppressant in first-time renal transplant recipients.
- Trial name
- NCT04903054
- Testing
- Lulizumab, Tacrolimus, Thymoglobulin®
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation
Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
Current therapy to prevent organ rejection relies on the use of calcineurin inhibitors either cyclosporine or tacrolimus. Although these agents have been very successful in preventing early acute rejection, this success has not…
- Trial name
- NCT00896012
- Testing
- Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University at Buffalo
Kidney Transplant Rejection
Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation
This study will evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult participants undergoing first kidney transplantation.
- Trial name
- LEGACY (NCT07835581)
- Testing
- Tegoprubart, Tacrolimus
- Volunteers
- 620 people
- Sponsor
- Eledon Pharmaceuticals
First Cadaveric Renal Graft
Evaluation of an Early Screening Test of Chronic Rejection and of Operational Tolerance by MicroArray in Renal Graft (Protocol DPRC Array)
The aim of the study is to explore the possibility to identify, at an early stage after a renal graft and from blood samples collected within first months after graft, a predictive transcriptional profile of long term occurence…
- Trial name
- NCT00746057
- Testing
- DNA chip
- Where
- France
- Volunteers
- 134 people
- Sponsor
- Nantes University Hospital
Kidney Transplant
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
This research study is being done to learn if an experimental treatment of infusing allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC ) directly into the renal artery is safe and can help reduce inflammation in the…
- Trial name
- NCT05456243
- Testing
- Low dose adipose tissue derived mesenchymal stromal cells (A-MSC), High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Kidney Transplant Rejection
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
Kidney transplant rejection remains a significant challenge to long-term graft survival. While histological biopsy continues to be the gold standard for diagnosing rejection, noninvasive biomarkers such as donor-derived cell-free…
- Trial name
- NCT07415876
- Testing
- Retrospective Cohort Enrollment, Prospective Cohort Enrollment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Prevention of Rejection in Kidney Transplant
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
- Trial name
- NCT05027906
- Testing
- AT-1501
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 48 people
- Sponsor
- Eledon Pharmaceuticals
Kidney Transplant Rejection
TruGraf® Long-term Clinical Outcomes Study
This is a prospective, multi-center, observational study. Subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at study enrollment and thereafter every 3 months.
- Trial name
- NCT04491552
- Testing
- Patients monitored with TruGraf and TRAC testing
- Where
- 36 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Transplant Genomics, Inc.
Kidney Transplantation
Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients
About one third of prospective kidney transplant recipients have antibodies in their blood directed against the tissues of their only available kidney donor.
- Trial name
- RAPTURE (NCT00371904)
- Testing
- Rituximab, Standard Care
- Where
- 3 sites in Australia
- Volunteers
- 192 people
- Sponsor
- Hunter and New England Health
Renal Transplant Rejection, Renal Transplant Failure
Heme Arginate in Transplantation Study
Organ shortage for transplant has necessitated use of kidneys from older donors, increasing the chance that the kidney will not work immediately or for as long as expected.
- Trial name
- HOT2 (NCT03646344)
- Testing
- Heme Arginate 25 MG/ML, 0.9% Sodium-chloride
- Where
- 2 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- University of Edinburgh
Kidney Rejection Transplant
Molecular Transcriptomics in Diagnosing Pediatric Kidney Transplant Rejection: the PANDA-Kids-ATLAS Study
Children with kidney failure have markedly increased mortality and face repeated transplantation over their lifetime due to limited allograft half-life (12-15 years).
- Trial name
- NCT07091214
- Where
- France
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Decreased Immunologic Activity [PE], Influenza
Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients
In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There is no data concerning the immunogenicity nor the security of the adjuvanted-A/H1N1 vaccine in renal disease patients.
- Conditions
- Decreased Immunologic Activity [PE], Influenza, Rejection
- Trial name
- NCT01298102
- Testing
- Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)
- Where
- Belgium
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Kidney Failure
Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
This study will test the safety and effectiveness of two drugs, Sirolimus and Thymoglobulin, for preventing rejection of transplanted kidneys.
- Trial name
- NCT00006178
- Testing
- Sirolimus, Thymoglobulin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Transplant Rejection
SRDK0921_ Analytical Performance Study
Analytical Performance Study of the SRDK0921 IVD medical device (Kit and Software)
- Trial name
- SRDK0921_APS (NCT05747274)
- Testing
- SRDK0921
- Where
- France
- Volunteers
- 439 people
- Sponsor
- BioMAdvanced Diagnostics
Renal Transplantation
A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac
This is a retrospective analysis of two different cohorts of patients that has undergone renal transplantation. This is a matched pair analysis of 100 patients treated with generic tacrolimus that will be compared with 100…
- Trial name
- GenTac (NCT02587052)
- Testing
- Generic tacrolimus, Prograf
- Where
- Sweden
- Volunteers
- 186 people
- Sponsor
- Vastra Gotaland Region
Kidney Transplantation
24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients
This study will provide continued treatment and assess the long term safety, efficacy and tolerability of oral AEB071 plus tacrolimus vs. mycophenolic acid plus tacrolimus after kidney transplantation.
- Trial name
- NCT00555789
- Testing
- AEB071, mycophenolic plus tacrolimus
- Where
- 27 sites in United States, Canada and 6 more
- Volunteers
- 137 people
- Sponsor
- Novartis Pharmaceuticals